Context Therapeutics initiated with an Outperform at JMP Securities

JMP Securities initiated coverage of Context Therapeutics (CNTX) with an Outperform rating and $4 price target Context is a $97.8M market cap clinical-stage biotechnology company focused on developing next-generation T cell engaging bispecific antibody therapies to treat solid tumors, the analyst tells investors in a research note. The firm says the company is building an “innovative” portfolio of in-licensed clinical-stage TCE bispecific antibodies. It views the management team as “highly effective business development operators that have built a pipeline through opportunistic in-licensing of the three early-stage assets that are worth more than the sum of its parts.”